STAAR Surgical Company - 10-K Summary (Fiscal Year Ended Dec 29, 1995)
Business Context and Reporting Period
Company: STAAR Surgical Company (NASDAQ: STAA)
Reporting Period: Fiscal year ended December 29, 1995
Industry: Medical Devices (Ophthalmic Surgery)
Core Business: Developer, manufacturer, and distributor of products for micro or less invasive ophthalmic surgery. Primary revenue driver is "foldable" intraocular lenses (IOLs) for cataract surgery. The company is actively introducing new products: the Glaucoma Wick (glaucoma treatment), Implantable Contact Lenses (ICLs) for refractive surgery, and STAARVISC (viscoelastic solution).
Key Financial Metrics
| Metric (in thousands) | 1995 | 1994 | 1993 |
|---|---|---|---|
| Total Revenues | $34,694 | $27,353 | $20,076 |
| Gross Profit | $26,253 | $21,295 | $16,096 |
| Gross Margin | 75.7% | 77.9% | 80.2% |
| Operating Income | $7,088 | $5,517 | $1,931 |
| Net Income | $7,482 | $8,326 | $2,535 |
| Diluted EPS | $0.55 | $0.62 | $0.20 |
| Working Capital | $16,335 | $14,166 | $7,354 |
| Total Assets | $38,803 | $28,888 | $18,776 |
| Long-Term Debt | $1,212 | $572 | $0 |
| Cash & Equivalents | $3,767 | $3,204 | $1,401 |
Liquidity: Current ratio improved to 2.9:1 in 1995 (from 3.4:1 in 1994). The company maintains a $3 million revolving line of credit (utilized ~$2.5 million) and a Swiss credit facility (~$1.0 million outstanding).
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 26.8% to $34.7 million, driven by increased domestic demand for UV-absorbing IOLs and a 24% increase in international revenue share (up from 16% in 1994).
- Profitability: Net income decreased 10.1% to $7.5 million. This decline was primarily due to a reduction in the income tax benefit recognized in 1995 ($0.9 million) compared to 1994 ($2.4 million), as the company utilized net operating loss carryforwards.
- Cost Structure: Cost of goods sold increased as a percentage of revenue (24.3% vs 22.1%) due to lower pricing from managed care contracts and manufacturing inefficiencies during the restart of UV IOL production. Marketing expenses rose to $10.9 million to support international expansion and new product launches.
- Debt: Long-term debt increased to $1.2 million, primarily due to a loan for the Swiss manufacturing facility and equipment capital leases.
Guidance, Outlook, and Risks
- Product Pipeline: The company plans to introduce ICLs and STAARVISC in selected foreign countries in early 1996. FDA applications are planned for the Glaucoma Wick (510(k)), STAARVISC (PMA), and ICLs (IDE) in the first half of 1996.
- Market Outlook: Management expects foldable IOLs to capture 70-80% of the domestic market within 3-5 years. International adoption is expected to track domestic trends over 3-7 years.
- Capital Expenditures: Planned CapEx for 1996 is approximately $4 million to expand manufacturing capacity for IOLs, ICLs, and Glaucoma Wicks.
- Key Risks:
- Regulatory: Uncertainty regarding FDA approval timelines for new products (ICL, Glaucoma Wick, STAARVISC).
- Legal: Ongoing patent litigation with Allergan Medical Optics (infringement claims) and Alcon Laboratories (validity of core Mazzocco Patent). Outcomes are uncertain.
- Market Acceptance: New products (Glaucoma Wick, ICL) require surgeon education and face competition from established drug therapies and laser surgeries.
- Competition: Intense competition from major players including Allergan, Chiron, and Alcon.
Investor Verification Checklist
- Patent Litigation Status: Verify the current status and potential financial exposure of the lawsuits against Allergan and Alcon regarding the Mazzocco Patent and insertion apparatus.
- FDA Approval Timelines: Confirm the submission dates and expected review periods for the Glaucoma Wick, ICL, and STAARVISC products.
- International Revenue Mix: Monitor the growth rate of international sales (currently 23% of total) and exposure to foreign exchange fluctuations.
- Deferred Tax Assets: Assess the realizability of the $3.3 million deferred tax asset and the impact of future tax provisions on net income.
- Managed Care Pricing: Evaluate the sustainability of gross margins given the pressure from managed care providers on domestic IOL pricing.